Latest period
$303M
YoY change
-0.1%
5Y CAGR
+8.0%
Peak year (FY2024)
$291M
Latest annual
$291M
Stock-Based Compensation history chart for Biogen (BIIB) from 2016 to 2025
Latest: $291M
Stock-Based Compensation growth chart for Biogen (BIIB) from 2016 to 2025
Latest: -0.1%
Stock-Based Compensation history table for Biogen (BIIB) from 1989 to 2025
| FY2025 | $291M | -0.1% | -$400K | ||
| FY2024 | $291M | +10.2% | +$27M | ||
| FY2023 | $264M | +4.0% | +$10.1M | ||
| FY2022 | $254M | +6.5% | +$15.5M | ||
| FY2021 | $239M | +20.3% | +$40.3M | ||
| FY2020 | $198M | +8.8% | +$16M | ||
| FY2019 | $182M | +15.7% | +$24.8M | ||
| FY2018 | $158M | +23.0% | +$29.5M | ||
| FY2017 | $128M | -17.3% | -$26.8M | ||
| FY2016 | $155M | -4.1% | -$6.6M | ||
| FY2015 | $161M | +3.9% | +$6.1M | ||
| FY2014 | $155M | +13.9% | +$19M | ||
| FY2013 | $136M | +15.0% | +$17.7M | ||
| FY2012 | $119M | +4.9% | +$5.56M | ||
| FY2011 | $113M | -32.7% | -$54.8M | ||
| FY2010 | $168M | +4.3% | +$6.92M | ||
| FY2009 | $161M | +10.1% | +$14.7M | ||
| FY2008 | $146M | +18.7% | +$23.1M | ||
| FY2007 | $123M | -2.9% | -$3.65M | ||
| FY2006 | $127M | +232.4% | +$88.6M | ||
| FY2005 | $38.1M | +127.1% | +$21.4M | ||
| FY2004 | $16.8M | — | +$16.8M | ||
| FY2003 | $0.00 | -100.0% | -$2.36M | ||
| FY2002 | $2.36M | — | +$2.36M | ||
| FY2001 | $0.00 | — | $0.00 | ||
| FY2000 | $0.00 | — | $0.00 | ||
| FY1999 | $0.00 | — | $0.00 | ||
| FY1998 | $0.00 | — | $0.00 | ||
| FY1997 | $0.00 | — | $0.00 | ||
| FY1996 | $0.00 | — | $0.00 | ||
| FY1995 | $0.00 | — | $0.00 | ||
| FY1994 | $0.00 | — | $0.00 | ||
| FY1993 | $0.00 | — | $0.00 | ||
| FY1992 | $0.00 | — | $0.00 | ||
| FY1991 | $0.00 | — | $0.00 | ||
| FY1990 | $0.00 | — | $0.00 | ||
| FY1989 | $0.00 | — | — |
- FY2025$291M-0.1%
- FY2024$291M+10.2%
- FY2023$264M+4.0%
- FY2022$254M+6.5%
- FY2021$239M+20.3%
- FY2020$198M+8.8%
- FY2019$182M+15.7%
- FY2018$158M+23.0%
- FY2017$128M-17.3%
- FY2016$155M-4.1%
- FY2015$161M+3.9%
- FY2014$155M+13.9%
- FY2013$136M+15.0%
- FY2012$119M+4.9%
- FY2011$113M-32.7%
- FY2010$168M+4.3%
- FY2009$161M+10.1%
- FY2008$146M+18.7%
- FY2007$123M-2.9%
- FY2006$127M+232.4%
- FY2005$38.1M+127.1%
- FY2004$16.8M—
- FY2003$0.00-100.0%
- FY2002$2.36M—
- FY2001$0.00—
- FY2000$0.00—
- FY1999$0.00—
- FY1998$0.00—
- FY1997$0.00—
- FY1996$0.00—
- FY1995$0.00—
- FY1994$0.00—
- FY1993$0.00—
- FY1992$0.00—
- FY1991$0.00—
- FY1990$0.00—
- FY1989$0.00—
Stock-Based Compensation values are taken from Biogen's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Stock-Based Compensation at Biogen (BIIB)
Stock-Based Compensation for Biogen (BIIB): headline value $303M · YoY -0.1%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual stock-based compensation for Biogen (BIIB) came in at $291M – edged down 0.1% year-over-year.
Across 2020–2025 (5 years), Biogen stock-based compensation produced a CAGR of +8.0% – with mixed annual results across the window.
2024 marks the peak stock-based compensation at $291M, with the historical low of $0.00 recorded in 1989.
Biogen Stock-Based Compensation by Year
Biogen Stock-Based Compensation 2025: $291M
Biogen stock-based compensation in 2025 was $291M, edged down 0.1% below 2024.
Biogen Stock-Based Compensation 2024: $291M
2024's stock-based compensation for Biogen came in at $291M, grew 10.2% from 2023. This figure represents the highest annual value in the available history.
Biogen Stock-Based Compensation 2023: $264M
Biogen posted stock-based compensation of $264M in 2023, edged up 4.0% from 2022.
Biogen Stock-Based Compensation 2022: $254M
In 2022, Biogen reported stock-based compensation of $254M, grew 6.5% from 2021.
Biogen Stock-Based Compensation 2021: $239M
Biogen stock-based compensation in 2021 was $239M.
See more financial history for Biogen (BIIB).
Sector peers by Stock-Based Compensation
Healthcare peers of Biogen (BIIB), ranked by their latest stock-based compensation
| $1.35B | |
| $971M | |
| $955M | |
| $626M | |
| $494M | |
| $310M | |
| $0.00 | |
| $0.00 |
- $1.35B
- $955M
- $626M
- $494M
- $0.00
- $0.00
Frequently asked questions
Biogen (BIIB) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.